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A B S T R A C T
The total number of 542 patients with colorectal cancer surgery have been analyzed in order to estimate the effect of re-
ceiving transfusion local recurrences, and the disease free – survival. It should be examined whether there are changes in
general immunity indicators which would be connected with perioperative transfusion. A significant connection has
been found between local recurrences and blood transfusion (p<0.0001), the most noticeable being in Dukes A (p=0.045),
localization on rectum (p=0.036). The receiving of blood transfusion is linked significantly with disease free – survival
reduction (p=0.0068; log rank), the most significant being in Dukes A stage (p=0.0123; log rank) and with localization
on rectum (p=0.0231). The analysis of general immunity indicators has shown significant immunocompromitation of
patients just before the surgery and this could have effect on immunomodulation caused by transfusion and just as on the
treatment prognosis of colorectal carcinoma.
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Introduction
Intravenous blood transfusion introduces large quan-
tities of foreign antigens, i.e. peripheral blood cells, pro-
teins, lipids, preservatives and anticoagulants. Tests on
animal models showed that the intravenous infusion of
allogeneic tissue leads to immunosuppression. The me-
chanism of development of natural immunological toler-
ance was explained in classic experiments by Medwar,
which showed that exposure to foreign bodies during the
fetal life leads to lifelong acceptance of skin transplants
taken from organism to which the animal was exposed
during its fetal life1.
Those and similar studies have given hope that the
tolerance may also be stimulated in patients who were
intended for transplantation, and that this would help to
reduce the rejection of the transplant. Clinical studies in
the later period confirmed the assumption that the use of
blood preparations prior to kidney transplantation was a
very successful method for improved survival of renal
allograft2.
Previous research on the animal model proved that
the infusion of extracts of different tissues from the
allogeneic donor before the tumor implantation acceler-
ated growth of the tumor3.
Gantt’s hypothesis4 that the immunosuppressive in-
fluence of transfusion, which was noticed in kidney
transplantations, can suppress immunological functions
in patients with malignant diseases and in that way con-
tribute to the appearance of local relapse and distant
metastases, had been investigated for more than 20 years
in over 130 studies, most of them related to colorectal
cancer, is still controversial and without final conclusion.
Nor random studies5–8, nor meta-analyses9–12 have
provided the answer of whether the allogeneic transfu-
sion influences the outcome of treatment of colorectal
cancers or not. The transfusion of allogeneic blood causes
in the recipient the change in immunological respon-
se13,14, such as the reduction of NK activities and T
lymphocytic blastogenesis, and the increase of suppres-
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sive T lymphocytic activity, which can, it is assumed, re-
duce the resistance to the infection or lead to dissemina-
tion of malignant cells.
The studies of the influence of allogeneic blood trans-
fusion on specific changes in immunological functions
were carried out. The following was observed: reduced
secretion of interleukin 2 (IL-2)15, reduced activity of
natural killer cells (NK cells)16, reduced proportion of T
lymphocyte helper cells (CD 4+ cells) / cytotoxic T lym-
phocytes (CD 8+ cells) – CD 4/CD 8 proportion14, re-
duced macrophagic functions17, and reduction of post-
poned type of oversensitivity18.
Clinical syndromes, whose mechanism is still to be de-
fined, connected with transfusions of allogeneic blood in
medical literature are called allogeneic blood transfusion
– associated immunomodulation (TRIM)19.
The goal is to investigate whether there is connection
in patients operated on account of colorectal cancer, be-
tween the appearance of local relapse and periods of dis-
ease free-survival with the transfusion and the quantity
of perioperative blood compensation, and to investigate
whether there are changes in indicators of general im-
munity which are related to perioperative blood compen-
sation.
Review of the databases showed that thus far not one
analysis of the influence of perioperative allogeneic blood
compensation in patients operated on account of colo-
rectal cancer has analyzed the influence of preoperative
immunological stage on the possible influence of allo-
geneic transfusion on the outcome of the treatment.
Patients and Methods
We analyzed the patients who were operated on ac-
count of colorectal cancer in the »Sisters of Mercy« Clini-
cal Hospital in Zagreb in the period from 1995 – 1999,
who in the moment of operation did not have distant
metastases, were not operated on if they were in an inop-
erable stage or if the palliative operation had been per-
formed. The patients who died during the postoperative
period of 30 days, and those who had primary relapsing
colorectal cancer were not included in the study. The re-
search also excluded patients who in the period of one
month before they were admitted received some kind of
blood preparation, who had malignant tumors of other
localization, autoimmune diseases, who had corticoste-
roid therapy, and those whose patohistological analysis
determined that their resection margine is not tumor-
-free.
The data on the acceptance of blood derivatives in
perioperative period were recorded – immediately before
the surgical intervention, during the operation of co-
lorectal cancer and in the first ten days of the postopera-
tive period. The mentioned period is defined as peri-
operative period. The transfusion has been defined as
reception of any other blood preparation: erythrocyte
concentrate, full blood or fresh frozen plasma. The quan-
tity of transfusion was also measured: non-reception or
reception of less than 500 ml, more than 500 and less
than a thousand milliliters, and more than a thousand
milliliters of transfusion. Since most of the patients who
received the transfusion also received a combination of
several preparations, the analysis of the influence of sep-
arate blood preparations was not possible because of mix-
ing of accompanying effects.
The operated patients were postoperatively monito-
red in days after the surgical intervention. During con-
trol examinations, the data about the manifestation of
cancer relapse were registered local relapses and distant
metastases and/or death, up to 1825 days after the opera-
tion.In some randomly chosen patients we measured the
indicators of general immunity one day before the opera-
tion and on the tenth day after the operation. The scope
of subjects was from 42 to 75. Stage of colorectal cancer
according to Dukes, as well as the localization in those
subjects, were equally represented in patients in all per-
formed analyses.
Also, the same immunological parameters were mea-
sured in healthy subjects. The scope of healthy exa-
minees was from 45 to 239. Immunoassays were per-
formed at the Immunology Department at the Clinic for
the Oncology and Nuclear Medicine at the »Sisters of
Mercy« Clinical Hospital.Blood for the analysis of immu-
nological parameters was taken one day before the oper-
ation, and on the tenth day after the operation. In order
for the subjects to be accepted for this study, they needed
to fulfill the following criteria: not to have received blood
preparation transfusion one month before the beginning
of the study, not to have had an intestinal obstruction,
perforation, intraabdominal abscess, nor the signs of
acute inflammatory disease which would influence their
immunological status. All patients who were included in
this study were operated by surgeons who specialized in
colorectal surgery. None of the patients whose immuno-
logical indicators were measured on the tenth postopera-
tive day showed signs of sepsis, anastomosis dehiscence,
pneumonia, urological infection, or anything that would
affect the immunological parameters. All patients whose
general immunity indicators were measured on the tenth
postoperative day received some transfusion preparation
– erythrocyte concentrate, full blood or fresh frozen
plasma. Prior to the operation, the values of immunologi-
cal parameters between the healthy subjects and those
who had colorectal cancer were compared. Since all pa-
tients received some kind of blood preparation, in the
analysis of impact of transfusion on immunological sta-
tus the patients were divided in respect to the median of
received blood preparations. Out of the indicators of gen-
eral immunity, functional and morphological changes
were measured:
– the number of leukocytes, percentage and total
number of granulocytes, lymphocytes and mono-
cytes (from standard smears of peripheral blood);
– percentage and total number of T lymphocytes and
their subpopulations (CD 4 and CD 8), B lympho-
cytes (surface immunoglobulins) and natural killer
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cells (NK cells, CD 56) by monoclonal antibodies us-
ing the method of immunofluorescence;
– functional tests for determining NK activities (cyto-
toxicity with 51Cr-K562) and phagocytic functions
of granulocytes and monocytes (fluorescence with
acridine orange and live saccharomyces as target
cells).
The instruments and methods used for determining
immunological parameters are:
– the light microscope OPTON Axioskop (peripheral
blood smears analyzed)
– surface immunocompetent cells (CD 3, CD 4, CD 8,
CD 56) were determined with fluorescent micro-
scope with the help of OPTON photomicroscope
equipped with epifluorescent condenser III RS;
– the fluorescent method was used to determine pha-
gocytic functions of granulocytes and monocytes, by
coloring with acridine orange and with saccharo-
myces as target cells. The results were examined
with OPTON photomicroscope with the use of epi-
fluorescent condenser III RS;
– the radioactive method was used to determine NK –
activity with the target cells K-562 marked with
chrome 51CR. Radioactivity released in the super-
natant of incubation mixture was measured with
LKB gamma-counter, model 1272 Clinigamma.
The process of determining fagocytic functions of gra-
nulocytes and monocytes. After the incubation of phago-
cytes with microorganisms, the preparations were col-
ored with acridine orange and microscoped under the
ultraviolet light. Dead microorganisms fluoresce red, and
the live ones green. The level of microbicidity was deter-
mined by comparing the number of ingested dead micro-
organisms in relation to the total amount of ingested par-
ticles.
The process of determining the ingestion and intra-
cellular microbicidity by fluorescence with the aid of
saccharomyceses as target cells. With the addition of hep-
arin, peripheral blood sediments, which results with the
separation of plasma rich in white blood cells which are
then rinsed, counted and their concentration set to a de-
termined value. At the same time, a culture of sac-
charomyceses is prepared, which are then washed and
their concentration set to a determined value. On the
slide, with the help of a small plastic ring and vaseline, a
chamber is prepared in which a prepared cell suspension
is pipetted and incubated in an incubator for cell culture
for 30 minutes, because of the sedimentation of cells and
adherence to the base. Non-adhered cells are then rinsed,
and fungus suspension is added into the chamber, then it
is incubated in the incubator for cell culture, free fungi
are rinsed, the cells which adhered to the glass are col-
ored with acridine orange and then microscoped under
ultraviolet light at the increase of 80x. In that way we
have obtained the data on:
a) type of phagocytes (monocyte, granulocyte)
b) number of ingested fungi (ingestion index)
c) percentage of cells which fagocyted (phagocytic ac-
tivity)
d) number of dead, killed fungi (percentage of micro-
bicidity).
Determining of NK-activity. Mononuclear cells from
peripheral blood were separated in Ficoll-Hypaque gradi-
ent (Pharmacia, Sweden) and incubated with 51Cr-K562
target cells in RPMI cell culture (Institute for Immunol-
ogy, Croatia) which contains 10 % of calf serum (Ru|er
Bo{kovi} Institute, Zagreb) by a proportion of 50:1 over
the period of 18 hours. Radioactivity measured with
gamma counter was expressed as percentage of cyto-
toxicity, as explained earlier.
The impact of transfusion and the quantity of re-
ceived transfusion in particular factors upon the appear-
ance of local relapses were compared with the standard
c2 test, with measurement of proportion of prospects and
limits – the confidence interval at the level of 95%.
Kaplan-Meier method was used to present the curve of
periods of disease free – survival, and differences in sur-
vival were compared by using the log-rank test and
Brestow test. In statistical processing the tests of rank
sum were used – Wilcoxon test and Mann-Whitney U
test.
Results
In the period from 1995 – 1999 on the Surgery Clinic
at the Sisters of Mercy Clinical Hospital in Zagreb, 711
patients were operated on account of colorectal cancer.
There were 542 (76%) patients who fulfilled the criteria,
stated above, for admission into the study, while 169
(24%) of patients did not fulfill the criteria.Dukes A was
found in 29.3 % (n=159), Dukes B in 37.8 % (n=205),
and Dukes C in 32.8 % (n=178) of patients.
The average reception of erythrocyte concentrate per
patient was 699.5 ml (median 580 ml), the reception of
full blood was 214 ml (median 0 ml), and fresh frozen
plasma 325 ml (median 190 ml).Statistically important
connection between the manifestation of local relapse
and transfusion was discovered (c2=11.774, df=1, p<
0.0001, Odds ratio – 5.139, CI 95% 1.833–14.412), and
also that the quantity of received transfusion is statisti-
cally significantly connected with the manifestation of lo-
cal relapses (c2=14.09, df=2, p=0.001). As for transfu-
sion, there was significant manifestation of local relapses
for rectum and rectosigmoid cancer (c2=4.836, df=1,
p=0.036, Odds ratio 3.581, CI 95 % 1.072–11.967), and
even more significant with regard to the quantity of re-
ceived transfusions (c2=9.766, df=2, p=0.008). There is
important connection between the manifestation of local
relapses in the transfusion for Dukes A in the data pro-
cessing with c2 test and obtained p value (c2=4.282,
df=1, p=0.045), but that is not confirmed by proportion
of prospects and the reliability interval of 95% (Odds ra-
tio 6.66, CI 95 % 0.856–51.666). Also, transfusions are
statistically marginally related to the manifestation of lo-
cal relapses in Dukes B (c2=4.301, df=1, p=0.53, Odds
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ratio 6.586, CI 95% 0.862–50.38). In Dukes C there was
no statistical connection found between the manifesta-
tion of relapse and transfusion (c2=2.477, df=1, p=
0.171, Odds ratio 3.153, CI 95% 0.704–14.114). In evalua-
tion of statistical significance of local relapses in respect
to the quantity of transfusions, there was significance in
Dukes A (c2=9.551, df=2, p=0.008), while in Dukes B
(c2=4.156, df=2, p=0.125) and Dukes C (c2=4.016, df=
2, p=0.134) no significant connection was found.There
was significant shortening of disease free – survival pe-
riod in patients who received transfusions (p=0.0069; log
rank, p=0.0139; Brestow signif) (Figure 1).
There was significant shortening of disease free – sur-
vival period in the increase of the quantity of received
transfusion (p=0.008; log rank, p=0.0139; Brestow sig-
nif) (Figure 2).
There was considerably shorter of disease free – sur-
vival period in case of transfusion for rectum cancer
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Fig. 1. Curve – disease free – survival period with regard
to transfusion.
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Fig. 2. Curve – disease free – survival period with regard
to quantity of received transfusion.
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to transfusion for rectum cancer.
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to transfusion for Dukes A.
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(p=0.0231; log rank, p= 0.0316; Brestow signif) (Figure
3), but not in respect to the quantity of received transfu-
sion (p= 0.0654; log rank, p=0.0867; Brestow signif).
There was no important influence to the disease free –
survival period in cases of colon cancer with transfusion
(p=0.3312; log rank, p=0.3643; Brestow signif), as well
as with regard to the quantity of received transfusion
(p=0.7853; log rank, p=0.6309; Brestow signif). It was
found that transfusion significantly shortens the disease
free – survival period in Dukes A (p=0.0123; log rank,
p=0.0131; Brestow signif) (Figure 4), as well as the
quantity of received transfusion (p=0.0026; log rank,
p=0.0021; Brestow signif) (Figure 5).
There was no influence of transfusion to the disease
free – survival period for Dukes B (p=0.2098; log rank,
p=0.3442; Brestow signif), as well as in respect to the
quantity of received transfusion (p=0.6273; log rank,
p=0.7151; Brestow signif). There was no influence of
transfusion on the disease free – survival period for
Dukes C (p=0.8413; log rank, p=0.8501; Brestow signif),
as well as in respect to the quantity of received transfu-
sion (p=0.8699; log rank, p=0.8338; Brestow signif).
There was significant decrease of lymphocyte per-
centage in patients (p=0.016), as well as of the total
number of lymphocytes (p=0.049), and the increase of
percentage of granulocytes (p<0.0001), as well as of the
total number of granulocytes (p=0.002) (Figure 6).
By comparison of patients with healthy subjects, it
was noticed that there was significant decrease of per-
centage of T lymphocytes – CD 3+ (p<0.0001), of total
number of CD 3+ (p=0.002), percentage of CD 4+ (p=
0.001), and percentage of CD 8+ (p= 0.015) (Figure 7).
There was significantly greater percentage of large
granulated lymphocytes in patients (p=0.024).
It was noticed that in patients, as compared to he-
althy subjects, there was significant decrease of percent-
age of granulocyte function (p=0.006), granulocytic in-
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gestion (p=0.003), percentage of granulocytic digestion
(p<0.0001), monocytic ingestion (p=0.008), percentage
of monocyte function (p=0.003), and percentage of NK
activity (p=0.003) (Figure 8).
In patients who received more than a median of trans-
fusion, there was significant decrease of percentage of
lymphocytes (p=0.01), significant increase of percentage
of granulocytes (p=0.013), and significant increase of to-
tal number of granulocytes (p=0.015), as well as of total
number of monocytes (p= 0.015) (Figure 9).
There were no changes in values of T lymphocytes
and their subpopulations (CD 4+, CD 8+) in patients af-
ter the operation, in respect to the median of received
transfusion in perioperative period.
There was decrease of value of total number of B lym-
phocytes in those who received more than a median of
transfusion preparations (p=0.022).
There were significantly higher values of percentage
of granulocytic digestion in patients after the operation,
in patients who received more than a median of blood
preparations (p=0.021).
Discussion
The mechanism of immunological changes, which em-
erge under the influence of transfusion, has not been
fully explained. Many authors believe that transfusion is
connected with cellular immunosuppression22–24.
Since the first report on the influence of transfusion
on the prognosis for colorectal cancer operation25, until
today, studies often dealt only with the survival in re-
spect to the reception or non-reception of transfusion
without including into the studies the other factors
which influence both the loss of blood during the opera-
tion and the manifestation of relapse of the disease. The
later studies started to include the other accompanying
factors in the analysis of transfusion influence. But it
was the work on randomized studies that provided the
clearer image of the possible influence of transfusion to
the relapse of colorectal cancer. Three randomized stud-
ies compared the frequency of relapse of cancer between
buffy-coat reduced allogeneic concentrate of erythrocytes
and receiver of autologous full blood7 or concentrate of
erythrocytes5 or leukocytes reduced, buffy-coat reduced,
concentrate of erythrocytes6, in patients who were oper-
ated on account of colorectal cancer. Generally, only one6
of those three studies reported on relation between allo-
geneic transfusion and relapse of cancer, and where the
control group comprised the patients who received leuko-
cyte reduced concentrates of erythrocytes.Only a few
studies had more than one hundred patients with Dukes
A26, and the same was reported by Beynon et al.27 in his
analysis in which he found out that there were not
enough patients with Dukes A to make the final conclu-
sion – in his analysis of 519 patients only 77 were those
with Dukes A. In that work, the patients who received
transfusion had the frequency of relapse 25.5 %, while in
the group who did not receive transfusion this frequency
was considerably lower and amounted to 6.7 %. Modin et
al.28 in 57 patients with Dukes A who had colon cancer,
found the unfavorable influence of transfusion on the pe-
riod of disease free – survival. According to Modin et al.28
period of disease free – survival for a six-year period for
patients who did not receive transfusion amounted to 69
%, while for patients who received transfusion it was 48
% (p < 0.05). Weiden et al.29 in his work even found the
favorable influence of transfusion in C2 stage on the re-
lapse of disease.
Our study, which included 156 patients in Dukes A, is
significant in that respect.Our results suggest that there
is connection between transfusion, and particularly the
quantity of received transfusion for rectum and recto-
sigmoid cancer with the manifestation of local relapses,
more than the influence on the disease free – survival pe-
riod. Localization of rectum and rectosigmoid cancer on
account of the nature of its localization, and frequent
forming of anastomosis deep in pelvis, opens up the ques-
tion of influence of transfusion on the prognosis of dis-
ease. Data on greater connection between transfusion,
and particularly the quantity of received transfusion to
the manifestation of local relapses, more than to the final
prognosis for disease, suggests that there is greater influ-
ence of the surgical operation and more aggressive ma-
nipulation of tumor in the narrow pelvis area, by which
the transfusion is just an indicator of such work, than
TRIM influence. The same conclusion was reached by
Busch et al.30 and Brand et al26.
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The immunological parameters in patients with colo-
rectal cancer and in healthy subjects we compared. It was
found out that there was significant deviation from nor-
mal distributions in differential blood count in patients
with colorectal cancer, in comparison with healthy sub-
jects. It can be seen that the number of leukocytes is not
significantly different between patients with colorectal
cancer and healthy subjects, while there is significant de-
crease of percentage of lymphocytes (p= 0.016), the total
number of lymphocytes (p= 0.049), and increased per-
centage of granulocytes (AP < 0.0001), as well as the to-
tal number of granulocytes (p= 0.001) (Figure 6).The in-
considerable difference in total number of leukocytes,
lymphopenia and relative granulocytosis was found by
Elsasser-Biele et al.31 and Ordemann et al32. Goto et al.33
also found the inconsiderable difference in the total
number of leukocytes, with significant decrease in the
number of lymphocytes, and even more significant de-
crease of percentage of lymphocytes in patients with sev-
eral different malignant tumors, as compared to healthy
subjects. Also, as well as in our sample, there was no sig-
nificant change of the total number and percentage of
monocytes33, Ordemann et al.32 discovered significant in-
crease of percentage of monocytes in patients with colo-
rectal cancer in relation to healthy subjects.
It was found out that the percentage (p<0.0001), as
well as the total number (p= 0.002) of T lymphocytes
(CD 3+) were significantly reduced in patients with colo-
rectal cancer, as compared to healthy subjects. The per-
centage of helper lymohocytes (CD 4+) is significantly re-
duced in patients (p= 0.001), but not the total number
CD 4+ (p= 0.249). Also, the percentage of cytotoxic lym-
phocytes (CD 8+) is significantly reduced in patients (p=
0.015), but not the total number (p= 0.125). The propor-
tion of CD 4/CD 8 did not change (p= 0.953, Figure 7).
Ordemann et al.32 discovered significant decrease of
CD 4/CD 8 ratio in patients with colorectal cancer in
comparison with healthy subjects (p=0.045). They also
noticed that with the progress of the disease, stronger
immunocompromise would appear. Goto et al.33 did not
find any significant difference between CD 4+ cells, CD
8+ cells and the proportion of CD 4/CD 8 between pa-
tients with cancer and healthy subjects.
It was observed that there was no significant difference
in the percentage and the total amount of B-lymphocytes,
between healthy subjects and patients. The percentage of
large granulated lymphocytes is significantly increased
in patients with colorectal cancer in comparison to healthy
subjects (p=0.024), although a significant difference in
the total amount (p=0.864) was not found. The percent-
age of NK cells is higher, but not significantly (p=0.064) in
patients with colorectal cancer, while the total amount
was not significantly altered (p=0.259).
Mentioned data suggest that there is a significant de-
crease of cell immunity in patients with colorectal cancer
in comparison to healthy subjects.
The most observable changes were found by tests mea-
suring phagocyte activity of granulocytes, monocytes and
NK activity in patients in relation to healthy subjects.
The percentage of phagocyte activity in granulocytes
is significantly reduced in patients (p=0.006). Likewise,
the granulocyte ingestion is significantly reduced in pa-
tients (p=0.003) and the percentage of granulocytes di-
gestion even more (AP<0.0001). It has been observed
that the function of monocyte ingestion is significantly
reduced in patients (p=0.008). The percentage of mono-
cyte digestion is not significantly changed in patients in
comparison to healthy subjefcts (p=0212). The percent-
age of monocyte function is significantly reduced in pa-
tients with colorectal cancer in comparison to healthy
subjects (p=0.001).
The percentage of NK activity is significantly reduced
in patients with colorectal cancer (p=0.003, Figure 8).
Many authors find that the influence of the amount of
received transfusions is an even more important factor
which influences the relapse of the illness in case of
colorectal cancer28,34–36. In patients who received less
than a median of blood preparations during the perio-
perative period no changes were observed in the total
number of leukocytes in comparison to those who receiv-
ed more than a median of blood preparations (p=0.131).
It has been observed that the percentage of lymphocytes
was significantly reduced in patients who received more
than a median of blood preparations (p=0.01), but the to-
tal amount of lymphocytes did not significantly change
(p=0.138), while the percentage of granulocyte signifi-
cantly increased (p=0.013), as well as the total amount of
granulocyte in patients who received more than a median
of blood preparations (p=0.023). The number of mono-
cytes was significantly increased in patients who re-
ceived more than amedian of blood preparations (p=0.015,
Figure 9).
No important difference was observed in subpopu-
lations of T lymphocytes (CD 4+, CD 8+, ratio CD 4 / 8) in
patients who received less, compared to those who re-
ceived more than amedian of blood preparations.A signifi-
cant decrease was observed in the total amount of B
lymphoytes in patients who received more than a median
of blood preparations (p=0.022), while the percentage of B
lymphocytes was marginally reduced (p=0.059). The total
number of large granulated lymphocytes, percentage of
NK cells (CD 56) and total amount NK cells (CD 56) were
not significantly changed. Ziv and al.37 also found out a
significant decrease in the number of B lymphocytes in
patients who received transfusion, and were operated on
because of colorectal cancer in Dukes C. Also they did not
find any important differences in percentage and total
amount of leukocytes, lymphocytes, T lymphocytes, help-
er T lymphocytes, cytotoxic T lymphocytes and NK cells,
in the first and the fifth week after the operation.
In our patients, who were divided in a different way, a
lymphopenia with reactive granulocytosis and monocy-
tosis was observed and, likewise, a significant decrease in
the total number of B lymphocytes which appeared with
the increase of the amount of transfusion.
Intake of antigens changes the flow of lymphatic cells
in lymph nodes and other lymphatic organs. During 24
hours after the intake of antigens, the lymphatic reactive
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clone completely disappears from the blood circulation
and can be found in the area of lymph nodes. In fact,
clone members accidentally enter the lymph node, but
then the reaction to the antigen retains them there. Only
after a couple of days, lymphocytes come out from the
lymph node, mostly in the shape of lymphoblasts, and
spread through the body. Mentioned facts are a possible
cause for the decrease in the number of B lymphocytes,
which this study observed in patients who received more
than a median of blood preparations.
In the test analysis of phagocyte functions of granulo-
cytes, monocytes and NK activity, a significant rise in the
percentage of granulocyte digestion was observed in pa-
tients who have takenmore than amedian amount of blood
preparations (p=0.021), while no significant results were
noticed in other tests. Kaplan et al.38 found a decrease in
the proportion of CD 4/8 in patients who received an
allogeneic transfusion, whereas Waymackas et al.39 found a
decrease in macrophages functions.On the whole, neither
of the previous analyses has taken into consideration that
patients were already immunocompromised before receiv-
ing transfusions, i.e. prior to the operation, which should be
taken into account in the future studies.
It is also possible that a different level of immuno-
compromise before the operation, which is linked to the
cancer stage, could be connected to the influence of
transfusion on the outcome of the treatment. In patients
with Dukes A, which are less immunocompromised be-
fore the very operation, immunocompromisation caused
by allogeneic transfusion could be strongly manifested,
while in patients with dissemination malignant illnesses
(Dukes C) this influence would not be manifested.
In the further research an analysis of the immunolog-
ical status should be carried out prior to the operation,
which would be connected with the stage of disease, then
patients should be divided according to the type of re-
ceived transfusion – autologous / leucoreduced vs. allo-
geneic, and a postoperational analysis of the immunolog-
ical status needs to be carried out. Furthermore, the
development of the local relapses and distant metastases
should be monitored, taking into account all prognostic
factors which influence the course of colorectal cancer
treatment. All of this would give a clearer picture of the
possible immunomodulation activity of allogeneic trans-
fusion.
R E F E R E N C E S
1. MEDWAR, P. B., Scand. J. Immunol., 33 (1991) 43. — 2. OPELZ,
G., D. P. SENGAR., M.R. MICKEY, P. I. TERASAKI, Transplant. Proc., 5
(1973) 253. — 3. KALISS, N., G. D. SNELL, Cancer Res., 11 (1951) 122.
— 4. GANTT, C. L., Lancet, 2 (1981) 363. — 5. HEISS, M. N., W.
MEMPEL, C. DELANOFF, K. JAUCH, C. GAPKA, M. MEMPEL, H. J.
DIETERICH, H. J. EISSNER, F. W. SCHILDBERG, Clin. Oncol., 12
(1994) 1859. — 6. HOUBIERS, J. G. A., A BRAND, L. M. G. VAN DE WA-
TERING, J. HERMANS, P. J. M. VERWEY, A. B. BIJNEN, P. PAHL-
PLATZ, M. E. SCHATTENKERK, T. WOBBES, J. E. DE VRIES, P. KLE-
MENTSCHITSCH, A. H. M. VAN DE MAAS, C. J. H. VAN DE VVELDE,
Lancet, 344 (1994) 573. — 7. BUSCH, O. R. C., W. C. J. HOP, M. A. W. H.
VAN PAPENDRECHT MAWH, R. L. MARQUET, J. JEEKEL, N. Engl. J.
Med., 328 (1993) 1372. — 8. VANDEWATERING, L. M. G., A. BRAND, J.
G. A. HOUBIERS, W. M. K. KRANENBARG, J. HERMANS, C. J. VANDE
VELDE CJ, Br. J. Surg., 8 (2001) 267. — 9. AMATO, A. C., M. PESCA-
TORI, Dis. Colon. Rectum., 5 (1998) 570. — 10. VAMVAKAS, E., 35
(1995) 35:760. — 11. CHUNG, M, O. K. STEINMETZ, P. H. GORDON, Br.
J. Surg., 80 (1993) 427. — 12. MC ALISTER, F. A., H. D. CLARK, P.S.
WELLS, A. LAUPACIS, Br. J. Surg., 85 (1998) 171. — 13. KAPLAN, J., S.
SARNAIK, J. GILTIAN J, J. LUSHER, Blood, 64 (1984) 308. — 14. GAF-
TER, U., Y. KALECHMAN, B. SREDNI, Kidney Int., 41 (1992) 143. — 15.
WOOD, M. L., R. GOTTSCHALK, A. P. MONAKO, Transplantation, 45
(1988) 930. — 16. JENSEN, L. S., A. J. ANDERSEN, P. M. CHRISTIAN-
SEN, P. HOKLAND, C. O. JOHL, G. MADSEN, J. MORTENSEN, C.
MOLLER-NIELSEN, F. HANBERG-SORENSEN, M. HOKLAND, Br. J.
Surg., 79 (1992) 513. — 17. WAYMACK, J. P., L. GALLON, U. BARCELLI,
J. W. ALEXANDER, Curr. Surg., 43 (1986) 305. — 18. NEILSEN, H. J., J.
H. HAMMER, F. MOESGAARD, H. KEHLET, Can. J. Surg., 34 (1991)
146. — 19. BLAJCHMAN M. A., Transfusion, 37 (1997) 121. — 20.
LUKA^, J., Z. KUSI], Clin. Croat., 32 (1993) 75. — 21. LUKA^, J., Z.
KUSI], D. KORDI], M. KON^AR, A. BOLAN^A, Breast Cancer Res.
Treat., 29 (1994) 279. — 22. BURROWS, L., P. TARTTER, Transfusion,
23 (1983) 419. — 23. TARTTER, P. I., D. M. FRANCIS, Transplant Proc.,
20 (1988) 1108. — 24. STEPHAN, E. N., J. M. KISALA, R. E. DEAN, A. S.
GEHA, I. H. CHAUDRY, Arch. Surg., 123 (1988) 235. — 25. BURROW, L.,
P. TARTTER, Transfusion, 23 (1983) 419. — 26. BRAND, A., J. G. A.
HOUBIERS: Immunomodulatory Effects of Blood Transfusion. (AABB
Press, Bethesda, 1999). — 27. BEYNON, J., P. W. DAVIES, P. J. BILL-
INGS, J. L. CHANNER, D. PRPTHEROE, H. C. UMPLEBY, N. J. MOR-
TENSEN, R. C. WILLIMSON, Dis. Colon Rectum, 29 (1989) 975. — 28.
MODIN, S., G. KARLSSON, L. WAHLBY, L. WHALBY, Eur. J. Surg. 158
(1992) 371. — 29. WEIDEN, P. L., M. A. BEAN, P. SCHULZ, Cancer 60
(1987) 870. — 30. BUSCH O. R. C., W. C. J. HOP, R. L. MARQUET, J.
JEKKEL, Ann. Surg. 220 (1994) 791. — 31. ELSASSER-BIELE, U., S.
VON KLEIST, R. FISHER, J. S. MONTING. J. Clin. Lab. Analysis, 6
(1992) 311. — 32. ORDEMANN, J., C. A. JACOBI, C. BRAUMANN, W.
SCHWENK, H. D. VOLK, J. M. MULLER, Int. J. Colorectal Dis.,17
(2002) 37. — 33. GOTO, S., M. SATO, R. KONEKO, M. ITOH, S. SATO, S.
TAKEUCHI, Cancer Immunol. Immunother., 48 (1999) 435. — 34.
TARTTER, P. I., Ann. Surg., 216 (1992) 633. — 35. STEUP, W. H., K.
HOJO, Y. MORIYA, K. SURIHAMA, S. MIZURO, J. HERMANS, C. J.
VAN DE VELDE, Hepatogastroenterology, 41 (1994) 253. — 36. BUSCH,
O. R., W. C. HOP, R. L. MARQUET, J. JEEKEL, Eur. J. Cancer., 31 (1995)
1226. — 37. ZIV, Y., B. SCOHAT, I. GELERENTER, Y. WOLLACH, Isr. J.
med. Sci., 27 (1991) 75. — 38. KAPLAN, J., S. SARNAIK, J. GITLIAN, J.
LUSHER, Blood, 64 (1984) 308. — 39. WAYMACK, J. P., L. GALLON, U.
BARCELLI, J. W. ALEXANDER, Curr. Surg., 43 (1986) 305.
S. Sabali}
Benka Benkovi}a 1/i, 23000 Zadar
e-mail: ssabali}@t-com.hr
S. Sabali} et al.: The Immunomodulation Effect of Allogenic Blood Transfusion in Colorectal, Coll. Antropol. 30 (2006) 4: 885–893
892
U:\coll-antropolo\coll-antro-4-2006\sabalic.vp
20. prosinac 2006 9:14:45
Color profile: Disabled
Composite  150 lpi at 45 degrees
IMUNOMODULACIJSKI U^INAK PRIMANJA TRANSFUZIJE KOD KOLOREKTALNOG KARCINOMA
S A @ E T A K
Analizirano je 542 bolesnika operiranih zbog kolorektalnog karcinoma radi procijene utjecaja primanja transfuzije
na pojavu lokalnih recidiva i na period bez bolesti – pre`ivljavanje. Istra`ene su promjene u pokazateljima op}e imu-
nosti i njihovu mogu}u povezanost sa perioperacijskom transfuzijom. Na|ena je zna~ajna povezanost pojave lokalnih
recidiva i primanja transfuzije (p<0,0001), najizra`enije kod Dukesa A (p=0,045), lokalizacije na rektumu i rekto-
sigmoidu (p=0,036). Koli~ina transfuzije najvi{e je povezana sa pojavom lokalnih recidiva kod Dukesa A (p=0,008),
lokalizacije na rektumu (p=0,008). Primanje transfuzije (p=0,0123; log rank) zna~ajno je povezano sa skra}enjem pe-
rioda bez bolesti – pre`ivljavanje, najzna~ajnije kod Dukes A stadija (p=0,0123; log rank), te pri lokalizaciji na rektumu
(p=0,0231; long rank). Analizom pokazatelja op}e imunosti uo~ena je zna~ajna imunokompromitacija bolesnika prije
same operacije, {to bi moglo djelovati na stupanj imunomodulacije uzrokovane transfuzijom, a tim i na prognozu lije-
~enja kolorektalnog karcinoma.
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